Cisatracurium Besylate Injection
Product Images NDC 0781-3153

This appears to be a chart or graph with percentages and a label for "MAP". However, without more context or a visual representation, it is not possible to provide a useful description beyond that.*

Cisatracurium Besylate Injection is a medication used for intravenous injection to cause respiratory arrest in patients. It is a paralyzing agent, therefore facilitation for artificial respiration must be immediately available. Each mL of the injection contains 2 mg cisatracurium besylate. The usual dosage of the medication can be found in the package insert. It is recommended to refrigerate the injection at a temperature between 2-8°C (36 to 46°F), but not to freeze it. Once removed from the refrigerator, it should be used within 21 days. The medication is manufactured in India by Gland Pharma Limited for Sandaz e, Princeton, NJ.*

Cisatracurium Besylate Injection is a paralyzing agent used for intravenous injection only. The injection is refrigerated and must be kept at 2° to 8°C to avoid freezing. Upon removal from refrigeration to room temperature, use within 21 days, even unrefrigerated. The injection is manufactured by Gland Pharma Limited in India for Sandoz, Inc. The package insert should be consulted for the usual dosage of the injection. The product is available in 200 mg/20 mL concentration, and each mL contains cisatracurium besylate equivalent to 10 mg of cisatracurium and water for Injection USP. The injection must be kept out of the reach of children. Facilities must be immediately available for artificial respiration.*